NO20080487L - Rekominant interferona2 (IFNa2) mutanter - Google Patents

Rekominant interferona2 (IFNa2) mutanter

Info

Publication number
NO20080487L
NO20080487L NO20080487A NO20080487A NO20080487L NO 20080487 L NO20080487 L NO 20080487L NO 20080487 A NO20080487 A NO 20080487A NO 20080487 A NO20080487 A NO 20080487A NO 20080487 L NO20080487 L NO 20080487L
Authority
NO
Norway
Prior art keywords
ifnα2
mutants
present
ifna2
recombinant
Prior art date
Application number
NO20080487A
Other languages
English (en)
Norwegian (no)
Inventor
Gideon Schreiber
Laila C Roisman
Diego Jaitin
Eyal Kalie
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of NO20080487L publication Critical patent/NO20080487L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20080487A 2005-06-29 2008-01-25 Rekominant interferona2 (IFNa2) mutanter NO20080487L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69481005P 2005-06-29 2005-06-29
PCT/IL2006/000754 WO2007000769A2 (fr) 2005-06-29 2006-06-28 Mutants d'interferon ?2 (ifn?2) de recombinaison

Publications (1)

Publication Number Publication Date
NO20080487L true NO20080487L (no) 2008-03-28

Family

ID=37595529

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080487A NO20080487L (no) 2005-06-29 2008-01-25 Rekominant interferona2 (IFNa2) mutanter

Country Status (12)

Country Link
US (2) US7767799B2 (fr)
EP (2) EP1909822B1 (fr)
JP (1) JP5208733B2 (fr)
CN (1) CN101304758B (fr)
AU (1) AU2006263331B2 (fr)
BR (1) BRPI0613098A2 (fr)
CA (1) CA2613737C (fr)
EA (1) EA014157B1 (fr)
ES (2) ES2436761T3 (fr)
HK (1) HK1125317A1 (fr)
NO (1) NO20080487L (fr)
WO (1) WO2007000769A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124086A2 (fr) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Activateurs chimériques, thérapies protéiniques à conception quantitative et leurs utilisations
MX349306B (es) 2007-09-21 2017-07-19 Univ California Interferón de objetivo demuestra actividades potentes apoptóticas y antitumorales.
WO2010030671A1 (fr) * 2008-09-09 2010-03-18 University Of Medicine And Dentistry Of New Jersey Antagonistes des interférons de type 1
WO2010080992A1 (fr) * 2009-01-09 2010-07-15 The Trustees Of The University Of Pennsylvania Régulateurs de la chaîne du récepteur 1 de l'interféron alpha (ifnar1) du récepteur d'interféron
WO2013059885A2 (fr) 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Produits de recombinaison de polypeptide et utilisations de ceux-ci
CN102584956B (zh) * 2012-02-13 2014-09-17 中山大学 一种慢性乙型病毒性肝炎相关基因ifna2的新突变蛋白、编码基因及其应用
CN102532300B (zh) * 2012-02-23 2013-07-17 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
CN102532299B (zh) * 2012-02-23 2013-07-17 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
DK2822575T3 (da) * 2012-03-03 2020-06-15 Immungene Inc Manipulerede, muterede antistof-interferon-fusionsmolekyler
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
US20150366944A1 (en) 2013-02-20 2015-12-24 Yeda Research And Development Co. Ltd. Interferon treatment targeting mutant p53 expressing cells
EP3677591B1 (fr) 2013-04-29 2022-12-28 Teva Pharmaceuticals Australia Pty Ltd Anticorps anti-cd38 et fusions sur un interféron alpha-2b atténué
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
CN105658669A (zh) * 2013-07-19 2016-06-08 弗拉芒区生物技术研究所 细胞因子拮抗剂的靶向
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
MX2017005481A (es) 2014-10-29 2017-10-26 Teva Pharmaceuticals Australia Pty Ltd Variantes de interferon a2b.
CN107556376B (zh) * 2017-09-08 2018-09-28 上海华新生物高技术有限公司 一种干扰素α-2b突变体及其制备方法和应用
CN108117595B (zh) * 2018-02-28 2020-06-26 中国科学院微生物研究所 一种犬α干扰素的制备及其应用
CN108752457B (zh) * 2018-05-23 2019-06-21 华中农业大学 一种来源于草鱼干扰素的衍生多肽及其应用
CN108997489B (zh) * 2018-09-04 2021-08-27 中国药科大学 干扰素突变体及干扰素突变体融合抗体及其制备方法、应用
CN110437328B (zh) * 2019-08-22 2021-06-04 安阳工学院 一种猪干扰素α突变体YNS及其制备方法和应用
AR117715A1 (es) * 2019-12-17 2021-08-25 Univ Nacional Del Litoral Unl Interferón hiperglicosilado con inmunogenicidad reducida
RU2741570C1 (ru) * 2019-12-26 2021-01-27 Генетик Диагностикс Энд Терапи 21 Лтд Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора GDTT1.8NAS12, несущий целевой ген, выбранный из группы генов IFNB1, IFNA14, IFNA2, IL12A, IL12B для повышения уровня экспрессии этих целевых генов, способ его получения и применения, штамм Escherichia coli JM110-NAS/GDTT1.8NAS12-IFNB1, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IFNA14, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IFNA2, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IL12A, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IL12B, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора
CN113440603B (zh) * 2020-03-26 2022-07-08 复旦大学 人α干扰素亚型及受体结合相关位点突变体在制备防治新型冠状病毒感染药物中的用途
WO2023230231A1 (fr) * 2022-05-25 2023-11-30 Malcolm Thomas Expression contrôlée de biomolécules thérapeutiquement pertinentes pour charges utiles localisées dans une lumière dans des nanovésicules biomimétiques et des exosomes
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
WO2024040247A1 (fr) 2022-08-18 2024-02-22 Regeneron Pharmaceuticals, Inc. Proprotéines d'interféron et leurs utilisations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JPH06510061A (ja) 1991-08-30 1994-11-10 ジェネンテク，インコーポレイテッド Ｉｄｄｍの治療法
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
TW249202B (fr) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
EP0859630B1 (fr) 1995-10-04 2002-12-11 Schering Corporation Combinaison de temozolomide et d'interferon alpha pour le traitement du cancer avance
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US20040002474A1 (en) 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
EP1251850B1 (fr) 2000-01-26 2006-06-21 Schering Corporation Preparation combinee dans la therapie du cancer
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
CA2471363C (fr) * 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Proteines hybrides d'albumine
WO2004022747A1 (fr) * 2002-09-09 2004-03-18 Nautilus Biotech Evolution de proteines dirigee, rationnelle faisant appel au balayage rationnel bidimensionnel de la mutagenese
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
CA2500626A1 (fr) * 2002-10-01 2004-04-15 Xencor, Inc. Variants d'interferons presentant des proprietes ameliorees
WO2004074486A2 (fr) * 2003-02-18 2004-09-02 Merck Patent Gmbh Proteines de fusion de muteines d'interferon-alpha aux proprietes ameliorees
WO2004089280A2 (fr) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Medicaments pegyles reversibles
RU2006104023A (ru) 2003-07-11 2006-07-27 Шеринг Акциенгезельшафт (De) УЛУЧШЕННЫЕ РЕКОМБИНАНТНЫЕ ПОЛИПЕПТИДЫ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА -БЕТА-1b
EP1789074A4 (fr) * 2004-08-09 2009-08-12 Alios Biopharma Inc Variants de polypeptides synthetiques hyperglycosyles resistants a la protease, formulations orales et leurs procedes d'utilisation

Also Published As

Publication number Publication date
ES2435846T3 (es) 2013-12-23
CN101304758B (zh) 2013-08-21
EA014157B1 (ru) 2010-10-29
EP2476428A1 (fr) 2012-07-18
US7767799B2 (en) 2010-08-03
US7919078B2 (en) 2011-04-05
EP1909822B1 (fr) 2013-09-25
AU2006263331A1 (en) 2007-01-04
CA2613737C (fr) 2017-05-23
WO2007000769A3 (fr) 2009-05-22
US20080279823A1 (en) 2008-11-13
WO2007000769A2 (fr) 2007-01-04
BRPI0613098A2 (pt) 2010-12-21
EP2476428B1 (fr) 2013-08-21
EA200800159A1 (ru) 2008-10-30
ES2436761T3 (es) 2014-01-07
JP5208733B2 (ja) 2013-06-12
US20080166319A1 (en) 2008-07-10
EP1909822A4 (fr) 2009-12-02
EP1909822A2 (fr) 2008-04-16
AU2006263331B2 (en) 2012-02-16
HK1125317A1 (en) 2009-08-07
JP2009501514A (ja) 2009-01-22
CA2613737A1 (fr) 2007-01-04
CN101304758A (zh) 2008-11-12

Similar Documents

Publication Publication Date Title
NO20080487L (no) Rekominant interferona2 (IFNa2) mutanter
CR9304A (es) Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA202190661A1 (ru) Агонисты фарнезоидного х-рецептора для лечения заболевания
WO2013049770A3 (fr) Méthodes de traitement du cancer
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
TW200630096A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
MX2009005398A (es) Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.
DE602005021696D1 (de) Indazolcarbonsäureamidverbindungen
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
ATE441646T1 (de) 5-ht4-rezeptoragonistenverbindungen
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
DK1957484T3 (da) Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
NO20076093L (no) Substituerte amidderivater som proteinkinaseinhibitorer
ATE431824T1 (de) Chinolinon-carboxamid-verbindungen
EA201290894A1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application